⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299972 | 1.00 | — | — | |
| SCHEMBL1299970 | 1.00 | — | — | |
| SCHEMBL31009685 | 0.90 | DPP4 (0.33) | — | |
| SCHEMBL25241058 | 0.90 | DPP4 (0.33) | — | |
| SCHEMBL30440041 | 0.82 | NR1H2 (0.36) | — | |
| SCHEMBL28338532 | 0.79 | GABRP (0.35) | — | |
| SCHEMBL1576861 | 0.78 | AGL (0.32) | — | |
| SCHEMBL21701012 | 0.78 | HTR2A (0.32) | — | |
| SCHEMBL21585767 | 0.78 | AGL (0.32) | — | |
| SCHEMBL1462712 | 0.78 | AGL (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| WO-2011028685-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |